…read more Source: The most popular stories and special reports in FierceBiotech Research, FiercePharmaManufacturing, and the rest of our Life Sciences publications
In biotech, here are the top 10 news stories of the year so far, based on web traffic. …read more Source: The top 10 FierceBiotech stories of 2014
…read more Source: Price of UniQure gene therapy tops €1.1M, Fund backs RET inhibitors, Promethera bags €25M
The FDA has slapped down Bristol-Myers Squibb’s closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy. …read more Source: FDA slaps down Bristol-Myers’ marketing pitch for hep C drug daclatasvir
Novartis has washed its hands of a researcher who admitted to falsifying results in a series of published papers, promising to dig into his work at the company to determine whether the pattern continued in its own labs. …read more Source: Novartis cans a researcher whose cooked data led to a slew of retractions
Scientists with the UC Irvine School of Medicine and the Italian Institute of Technology have spotlighted what they call the “very first class” of acid ceramidase inhibitors that could eventually go on to help amp up the effectiveness of chemotherapies. …read more Source: UC Irvine investigators feature a new class of ‘chemosensitizers’
The growing biotech hub in the Boston area has attracted drug developers virtual and multinational to set up shop near the bay, but the boom in demand is threatening to outstrip inventory, according to the Boston Business Journal. …read more Source: Biotech’s Boston blitz is making lab space harder–and costlier–to come by
What makes Woodford such a potent figure is the example he sets in backing global drug development, where even small companies knit together scientific, administrative and support functions from an international cast of players. …read more Source: It takes a planet: Woodford’s investment strategy may help change the global biotech scene
Ampio Pharmaceuticals has postponed a plot to spin out one of its subsidiaries through an IPO, citing unfavorable market conditions. …read more Source: Ampio calls off a $30M IPO for its men’s health offshoot
Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J’s Stelara in a head-to-head study. The news comes just two weeks after the pharma partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic. …read more Source: […]
